Experimental pseudocyst model resembling human ganglion.
There is no animal model of ganglion. We describe a simple and reproducible animal model of pseudocystic diseases. First, we experimented to establish a pseudocystic model. We used cylindrical glass implants (6 mm diameter, 30 mm long) to create fibrous capsules in rats. The implants were inserted in the subcutaneous tissue in the dorsum of rats. Sixty implants were carried out (two implants per rat). Twelve weeks after implantation, the glass implants were removed and 0.5 mL sodium hyaluronate solution was injected into each cavity. Next, we tested the model by histological examination after OK-432 administration. Microscopic examination revealed that the wall was composed of a layer of collagenous fibers similar to those noted in ganglia; the lumen was retained for 3 weeks. Histopathological changes after OK-432 administration showed nonspecific inflammatory response induced by OK-432, resulting in in vivo activation of many inflammatory cells and then fast and reliable closure of cavities. No harmful reactions to OK-432 were observed histopathologically. These data suggest that our experimental cyst is a suitable model for studying pseudocystic diseases. This model can be used for research evaluating safe drug doses, conducting therapeutic comparison of several agents, and histopathological time course studies of the affected tissues. OK-432 administration on this model showed the potential of one of the ideal agents to treat pseudocystic lesions like ganglion.
Taniguchi
Toshiko
T
Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, Osaka City University, Osaka, Japan. taniguchit@med.osaka-cu.ac.jp
Harada
Teruichi
T
Ohba
Norihiro
N
Motomura
Hisashi
H
Maeda
Mitsuyo
M
Ishii
Masamitsu
M
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D045888:Ganglion Cysts / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D015552:Injections, Intralesional; D008297:Male; D010844:Picibanil / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
D000970:Antineoplastic Agents; D010844:Picibanil